# FDA Standards for Tables, Listings, and Figures (TLFs)

## FDA Regulatory Requirements

### 1. ICH E3 Guidelines (Clinical Study Reports)
- **Structure and Content of Clinical Study Reports**
- **Section 14: Statistical Methods**
- **Section 16: Study Results**

### 2. FDA Guidance Documents
- **FDA Guidance for Industry: E3 Structure and Content of Clinical Study Reports**
- **FDA Guidance for Industry: E9 Statistical Principles for Clinical Trials**
- **FDA Guidance for Industry: E6 Good Clinical Practice**

### 3. CDISC Standards
- **SDTM (Study Data Tabulation Model)**
- **ADaM (Analysis Data Model)**
- **SEND (Standard for Exchange of Nonclinical Data)**

## Key TLF Categories

### 1. Demographics and Baseline Characteristics
- **Table 14.1.1**: Demographic Characteristics
- **Table 14.1.2**: Baseline Characteristics
- **Table 14.1.3**: Medical History

### 2. Efficacy Analysis
- **Table 14.2.1**: Primary Efficacy Endpoint
- **Table 14.2.2**: Secondary Efficacy Endpoints
- **Table 14.2.3**: Subgroup Analyses
- **Table 14.2.4**: Sensitivity Analyses

### 3. Safety Analysis
- **Table 14.3.1**: Adverse Events Summary
- **Table 14.3.2**: Adverse Events by System Organ Class
- **Table 14.3.3**: Serious Adverse Events
- **Table 14.3.4**: Laboratory Abnormalities
- **Table 14.3.5**: Vital Signs
- **Table 14.3.6**: ECG Results

### 4. Pharmacokinetics
- **Table 14.4.1**: PK Parameters Summary
- **Table 14.4.2**: Concentration-Time Profiles

### 5. Figures
- **Figure 14.1.1**: Patient Disposition
- **Figure 14.2.1**: Primary Endpoint Results
- **Figure 14.3.1**: Adverse Events Profile
- **Figure 14.4.1**: PK Concentration Profiles

## FDA Compliance Requirements

### 1. Statistical Standards
- **Intent-to-Treat (ITT) Population**
- **Per-Protocol Population**
- **Safety Population**
- **Missing Data Handling**
- **Multiple Testing Adjustments**

### 2. Reporting Standards
- **N and n reporting**
- **Percentages with denominators**
- **P-values and confidence intervals**
- **Effect sizes and clinical significance**
- **Subgroup analyses**

### 3. Quality Standards
- **Data quality checks**
- **Statistical review**
- **Clinical review**
- **Regulatory review**

## High-Quality CSR Examples

### 1. Moderna COVID-19 Vaccine (mRNA-1273)
- **Comprehensive safety and efficacy data**
- **Large sample size (30,000+ participants)**
- **Multiple endpoints and subgroups**
- **Detailed statistical methodology**

### 2. Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)
- **Robust statistical analysis**
- **Comprehensive safety profile**
- **Multiple age groups and populations**
- **Detailed efficacy by variant**

### 3. AstraZeneca COVID-19 Vaccine (AZD1222)
- **International multicenter study**
- **Multiple dosing regimens**
- **Comprehensive safety analysis**
- **Detailed efficacy by age and comorbidity**

## Best Practices for TLF Generation

### 1. Template Structure
- **Clear title and numbering**
- **Population definition**
- **Statistical methodology**
- **Footnotes and annotations**
- **Source data references**

### 2. Statistical Methodology
- **Appropriate statistical tests**
- **Handling of missing data**
- **Multiple comparison adjustments**
- **Sensitivity analyses**

### 3. Clinical Interpretation
- **Clinical significance**
- **Safety considerations**
- **Risk-benefit assessment**
- **Regulatory implications**

## R Code Standards

### 1. Reproducibility
- **Set random seeds**
- **Version control**
- **Documentation**
- **Validation checks**

### 2. Quality Control
- **Data validation**
- **Statistical validation**
- **Clinical review**
- **Regulatory review**

### 3. Performance
- **Efficient algorithms**
- **Memory management**
- **Parallel processing**
- **Error handling** 